Chronic kidney disease: A major concern in liver transplantation in the XXI century  by Solà, Elsa & Ginès, Pere
EditorialChronic kidney disease: A major concern in liver transplantation
in the XXI century
Elsa Solà, Pere Ginès⇑
Liver Unit, Hospital Clinic, University of Barcelona, Spain
See Article, pages 286–292With an approximate 12,000 transplants performed annually in
Europe and the United States during recent years, liver transplan-
tation has become a very common treatment and in fact the only
curative method for most advanced chronic liver diseases [1,2].
Survival rates have increased gradually since the ﬁrst liver trans-
plants were performed in the 1960’s and current survival proba-
bility after 10 years of transplantation is above 60% [1,2].
With the steady increase in survival rates after liver trans-
plantation, some complications that were not frequently
observed in early years have become progressively apparent.
These complications include, among others, cardiovascular
events, metabolic diseases, including diabetes mellitus and
lipid disorders, extra-hepatic malignancies, and impairment in
kidney function. Among them, an important clinical issue is
Chronic Kidney Disease (CKD). There is a large body of evi-
dence indicating that patients submitted to a liver transplant
have an increased risk of development of chronic and progres-
sive impairment of kidney function, which becomes particu-
larly relevant in long-term survivors [3–16]. The frequency of
CKD, as indicated by a marked reduction in glomerular ﬁltra-
tion rate (deﬁnitions have changed over time) or the need
for renal replacement therapy has been estimated to range
between 18 and 25% at 10 years of liver transplantation. With
the current deﬁnition [17], the observed frequency of CKD in
liver transplant recipients is even higher [7,10]. Factors associ-
ated with an increased risk of development of CKD after liver
transplantation include among others, serum creatinine levels
at transplant, GFR at one year of transplantation, age, female
sex, diabetes mellitus, and arterial hypertension. Non-alcoholic
steatohepatitis (NASH) as a cause of transplantation is
also associated with an increased risk of CKD after transplant
[4–8,10–13,16]. Few studies have provided a histological anal-
ysis of kidneys of patients developing severe CKD after liver
transplantation. Interestingly, and contrarily to what was
expected initially, only a limited proportion of cases of CKD
may be attributed to chronic toxicity related to calcineurinJournal of Hepatology 20
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Open access under CC BY-NC-ND license.inhibitors (cyclosporine or tacrolimus). By contrast, most
patients show histological changes characterized by glomerular
and/or interstitial abnormalities, suggestive in some cases of
diabetes and/or hypertensive nephropathy [14,15]. A consistent
observation of all studies reported is that the occurrence of
CKD is a major risk factor of death in liver transplant recipi-
ents. This ﬁnding emphasizes that the impairment of kidney
function is not a simple laboratory abnormality but a major
clinical issue in these patients that requires strict surveillance
and management of conditions associated with progression of
kidney dysfunction, particularly arterial hypertension and
metabolic conditions, speciﬁcally diabetes mellitus and lipid
disorders.
In this context, the study by Allen et al. published in the cur-
rent issue of the Journal of Hepatology, reports on the frequency
and outcome of CKD in all adult patients treated with liver trans-
plantation in a single institution over a 28-yr period [18]. The
study has several important strengths that make it a unique
investigation to assess the evolution of kidney function after liver
transplantation: (1) inclusion of a large and consecutive series of
patients (1211 patients); only patients with simultaneous multi-
ple organ transplantation or repeated liver transplantation were
excluded, thus avoiding selection bias; (2) long-term follow-up
(average follow-up of 6 years); (3) measurement of GFR at several
time points (5 measurements per patient in average) after liver
transplantation using iothalamate clearance which is a very pre-
cise method of measurement of GFR; and (4) use of time-depen-
dent statistical modeling. The main ﬁnding of the study is that
the proportion of patients with what can be considered a normal
GFR (>60 ml/min/1.73 m2) decreases dramatically over time after
liver transplantation, with only 19% of patients having normal
GFR after 25 years of transplantation. Moreover, at 25 years after
liver transplantation, 9% of the initial population had been trea-
ted with kidney transplantation, and among the remaining
patients, 57% had stage 3 CKD stage (GFR between 59 and
30 ml/min/1.73 m2), 19% stage 4 CKD (GFR between 29 and
15 ml/min/1.73 m2), and 5% stage 5 CKD (GFR <15 ml/min/
1.73 m2) (and only 19% maintained a normal GFR, as stated
above). Corresponding percentages for periods of time lower than
25 years can be seen in Fig. 1B of the manuscript [18]. It can
therefore be concluded that normal kidney function is the excep-
tion and not the rule for patients who survive for long periods of14 vol. 61 j 196–197
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time after liver transplantation. The current study also analyzed
the relationship between measured GFR and mortality. The risk
of death increased signiﬁcantly with a reduction in GFR below
30 ml/min, and was particularly increased at values of GFR below
15 ml/min. It is important to emphasize that estimated GFR using
existing formulas undervalued the risk of death compared to that
of GFR measured with iothalamate clearance. In fact, using esti-
mated GFR the increase in the risk of death did not become
apparent until it decreased below 45 ml/min.
In view of the ﬁndings of Allen et al. [18], as well as those
from previous studies, the development of CKD must be consid-
ered a major clinical issue in the evolution of patients submitted
to liver transplantation. Kidney function should be followed-up
in these patients with a close attention similar to that devoted
to the evaluation of liver function. Although the use of calcineu-
rin inhibitors can without doubt affect kidney function, results
of studies aimed at preventing the development of CKD based
on the substitution of these drugs by renal-sparing agents, such
as mycophenolate mofetil or sirolimus have been inconsistent
[discussed in ref [19]]. Therefore, prevention and treatment of
CKD requires a multidisciplinary approach based on the adjust-
ment of immunosuppressive drugs combined with an aggressive
treatment of factors predisposing to kidney dysfunction, includ-
ing obesity, arterial hypertension, diabetes mellitus, and lipid
abnormalities. With the anticipated reduction in the number
of patients transplanted for hepatitis C in the future due to
the recent introduction of the direct antiviral agents and the
increasing global incidence of obesity and diabetes mellitus, it
is plausible that the number of patients transplanted for cirrho-
sis or hepatocellular carcinoma associated with non-alcoholic
steatohepatitis will be on the raise in the next years. Since obes-
ity and metabolic disorders are strongly associated with the
development of CKD [20], the prevalence of CKD in liver trans-
plant recipients will probably increase further in the future. An
effort should be made to investigate the mechanisms involved
in the pathogenesis of CKD in liver transplant patients as well
as in therapeutic strategies to prevent its development. Without
this research effort, CKD will become one of the major clinical
issues in liver transplantation.Financial support
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